Prostate Cancer Treatment Articles & Analysis
12 articles found
Among the groundbreaking developments, cancer vaccines are a promising frontier1. These vaccines are transforming how we approach cancer treatment, leveraging the body's immune system to fight malignancies more effectively. ...
Flotufolastat F 18 binds to prostate-specific membrane antigen (PSMA) (IC50= 4.4 nM) expressed on cells, including prostate cancer cells. In patients with recurrent prostate cancer who require local treatment, positron emission tomography (PET) with an 18F-labeled ligand provides accurate ...
Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's ...
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the ...
While Movember is not just about prostate cancer, it is a great place to start; prostate cancer is the second most common cancer among men worldwide1, and the second leading cause of cancer death in American men.2 In the UK, more than 52,000 men are diagnosed with prostate ...
The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant prostate cancer to support decision-making and improve health outcomes for men suspected of having prostate cancer. ...
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. ...
” Recently, Nanostics announced positive results from the clinical validation study of its lead prostate cancer diagnostic test, ClarityDX Prostate®, showing 94% sensitivity, 37% specificity, 49% positive predictive value, and 90% negative predictive value for predicting clinically significant (grade group ≥2) ...
It is a medication used to treat prostate cancer. It is used in combination with corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). ...
The Alberta Prostate Cancer Research Initiative (APCaRI) co-sponsored clinical validation study is targeting the recruitment of 2,800 patients with elevated levels of prostate specific antigen (PSA). ...
With increased demand for low 103 Pd (palladium) seed sources, to treat prostate and eye cancers, new sources have been designed and introduced. This paper presents the two new palladium brachytherapy sources, IR03- 103 Pd and IR04- 103 Pd that have been developed at Agricultural, Medical & Industrial Research School . The dosimetric parameters, such as the dose rate constant Λ , ...
Prostate cancer is the second most commonly diagnosed cancer among North American men and the second leading cause of death in those aged 65 and over. The US Cancer Society recommends testing those over 50 years of age who are expected to live at least for 10 years, even though the ability of early detection to decrease prostate cancer mortality has not been demonstrated. A controversy exists ...